186493-53-8

Basic information

• Product Name: N-Methyl,N-{(3-bromo)-1-propyl}aniline
• Synonyms: N-Methyl,N-{(3-bromo)-1-propyl}aniline
• CAS NO: 186493-53-8
• Molecular Weight: 228.132
• Mol File: 186493-53-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: N-Methyl,N-{(3-bromo)-1-propyl}aniline(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methyl,N-{(3-bromo)-1-propyl}aniline(186493-53-8)
• EPA Substance Registry System: N-Methyl,N-{(3-bromo)-1-propyl}aniline(186493-53-8)

Safety Data

• Hazardous Substances Data: 186493-53-8(Hazardous Substances Data)

Upstream product

• 128622-94-6 N-(3-chloro-propyl)-N-methyl-aniline 
• 10035-10-6 hydrogen bromide 
• 34579-44-7 N-Methyl,N-{(3-hydroxy)-1-propyl}aniline 
• 109-64-8 1,3-dibromo-propane 
• 100-61-8 N-methylaniline 

Downstream Products

• 1452855-71-8 4-((3-(methyl(phenyl)amino)propyl)thio)phenol 
• 1431659-32-3 4-(3-(methyl(phenyl)amino)propoxy)phenol 
• 1235866-14-4 9-O-[3-(N-methyl-phenylamino)propyl]berberine bromide 
• 252967-02-5 N-Methyl-N-{(p-formylphenoxy)-1-propyl}aniline 
• 252967-01-4 N-Methyl-N-{(o-formylphenoxy)-1-propyl}aniline 
• 47233-87-4 N,N'-dimethyl-N,N'-diphenyl-1,6-hexanediamine 

Relevant articles and documents

Transition metal- And light-free radical borylation of alkyl bromides and iodides using silane

We report operationally simple and neutral conditions for borylation of alkyl bromides and iodides to alkyl boronic esters under transition metal- and light-free conditions. A series of substrates with a wide range of functional groups were effectively transformed into the borylation products in moderate to good yields. Mechanistic studies, including radical clock experiments and DFT calculations, gave detailed insight into the radical borylation process.

Targeted dendrimer-drug conjugates

The invention provides for dendrimer conjugates useful for liver-specific delivery of therapeutic agents. The therapeutic agent is associated to the dendrimer through a enzyme-cleavable covalent linkage.

ROS-Activated Compounds as Selective Anti-Cancer Therapeutics

Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.